[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616990":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":15,"studyPopulation":15,"armGroups":22,"interventions":35,"overallOfficials":15,"centralContacts":49,"locations":55,"responsibleParty":71,"collaborators":15,"id":73,"slug":15,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":15,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":15,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":15,"overallStatus":92,"whyStopped":15,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":15},[9,13],{"measure":10,"description":11,"timeFrame":12},"Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss)","AUCτ,ss","pre-dose (0hour) to 24 hours post-dose on Day 14",{"measure":14,"description":15,"timeFrame":12},"Maximum concentration of drug in plasma at steady state (Cmax,ss)",null,{"allocation":17,"interventionModel":18,"interventionModelDescription":15,"primaryPurpose":19,"observationalModel":15,"timePerspective":15,"maskingInfo":20},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":21,"maskingDescription":15,"whoMasked":15},"NONE",[23,30],{"label":24,"type":25,"description":26,"interventionNames":27},"Arm A","EXPERIMENTAL","Period 1 : Treatment A(AD-2321), Period 2 : Treatment C(AD-2321+AD-2322)",[28,29],"Drug: Treatment A(AD-2321)","Drug: Treatment C(AD-2321+AD-2322)",{"label":31,"type":25,"description":32,"interventionNames":33},"Arm B","Period 1 : Treatment B(AD-2322), Period 2 : Treatment C(AD-2321+AD-2322)",[34,29],"Drug: Treatment B(AD-2322)",[36,41,45],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":15},"DRUG","Treatment A(AD-2321)","AD-2321 Oral Tablet",[24],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":15},"Treatment B(AD-2322)","AD-2322 Oral Tablet",[31],{"type":37,"name":46,"description":47,"armGroupLabels":48,"otherNames":15},"Treatment C(AD-2321+AD-2322)","AD-2321 Oral Tablet+AD-2322 Oral Tablet",[24,31],[50],{"name":51,"role":52,"phone":53,"phoneExt":15,"email":54},"SoonKeun Kwon","CONTACT","+82318916915","skkwon@addpharma.co.kr",[56],{"facility":57,"status":15,"city":58,"state":15,"zip":15,"country":59,"countryCode":15,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"H+ Yangji Hospital","Seoul","South Korea",{"type":61,"coordinates":62},"Point",[63,64],126.9784,37.566,{"lat":64,"lon":63},[67],{"name":68,"role":52,"phone":69,"phoneExt":15,"email":70},"SeungHyun Kang","+82-70-4665-9490","juspa@newyjh.com",{"type":72,"investigatorFullName":15,"investigatorTitle":15,"investigatorAffiliation":15,"oldNameTitle":15,"oldOrganization":15},"SPONSOR","100616990",false,"NCT07312799","Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322","A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged ≥19 and \\\u003C65 years at the time of the screening visit\n* Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg\u002Fm² and 30.0 kg\u002Fm² at the time of the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","64 Years",{"count":84,"type":85},41,"ESTIMATED","INTERVENTIONAL",[88],"PHASE1","To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.",[91],"Hypertension","NOT_YET_RECRUITING","2025-12-17",{"date":95,"type":96},"2025-12-31","ACTUAL",{"date":98,"type":85},"2026-01-27",{"date":100,"type":85},"2026-02-26",{"name":5,"class":6},1]